LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Gilead Sciences Inc.

Gesloten

SectorGezondheidszorg

112.97 0.41

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

112.5

Max

113.03

Belangrijke statistieken

By Trading Economics

Inkomsten

645M

2B

Verkoop

414M

7.1B

K/W

Sectorgemiddelde

22.649

35.724

Dividendrendement

2.72

Winstmarge

27.68

Werknemers

17,600

EBITDA

769M

3.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+11.11% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.72%

3.09%

Volgende dividenddatum

29 sep 2025

Volgende Ex Dividend datum

15 sep 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-804M

142B

Vorige openingsprijs

112.56

Vorige sluitingsprijs

112.97

Nieuwssentiment

By Acuity

24%

76%

44 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Gilead Sciences Inc. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

21 aug 2025, 13:45 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Interius BioTherapeutics for $350 Million

7 aug 2025, 20:59 UTC

Winsten

Gilead Sciences Upgrades Guidance After 2Q Results Top Views

24 apr 2025, 20:17 UTC

Winsten

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

21 aug 2025, 12:35 UTC

Acquisities, Fusies, Overnames

Gilead Sciences Sees Transaction With Interius Cutting 2025 Adjusted EPS by 23c-25c >GILD

21 aug 2025, 12:31 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Interius is Private Biotechnology Company Developing In-Vivo CAR Therapeutics >GILD

21 aug 2025, 12:31 UTC

Acquisities, Fusies, Overnames

Gilead's Kite to Buy Interius BioTherapeutics for $350 Million >GILD

21 aug 2025, 12:30 UTC

Acquisities, Fusies, Overnames

Kite To Acquire Interius BioTherapeutics To Advance In Vivo Platform >GILD

8 aug 2025, 20:28 UTC

Winsten

These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More -- Barrons.com

8 aug 2025, 17:27 UTC

Winsten

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Microchip, and More -- Barrons.com

8 aug 2025, 12:03 UTC

Winsten

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Firefly -- Barrons.com

8 aug 2025, 11:13 UTC

Winsten

These Stocks Are Moving Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Firefly -- Barrons.com

7 aug 2025, 21:13 UTC

Winsten

Gilead Earnings Beat Estimates, But All Eyes Are On New HIV Shot -- Barrons.com

7 aug 2025, 20:44 UTC

Winsten

Gilead Sciences Ups Guidance After 2Q Results Top Views

7 aug 2025, 20:26 UTC

Winsten

Gilead Sciences: Liver Disease Portfolio Sales Decreased 4% to $795M in 2Q >GILD

7 aug 2025, 20:26 UTC

Winsten

Gilead Sciences: 2Q Descovy Sales Increased 35% to $653M >GILD

7 aug 2025, 20:25 UTC

Winsten

Gilead Sciences: HIV Pdt Sales Increased 7% to $5.1 B in 2Q >GILD

7 aug 2025, 20:24 UTC

Winsten

Gilead Sciences: 2Q Biktarvy Sales Increased 9% Yr-Over-Yr to $3.5 B >GILD

7 aug 2025, 20:22 UTC

Winsten

Gilead Sciences 2Q Adj EPS $2.01 >GILD

7 aug 2025, 20:22 UTC

Winsten

Gilead Sciences 2Q Net $1.96B >GILD

7 aug 2025, 20:22 UTC

Winsten

Gilead Sciences Sees FY EPS $5.85-EPS $6.15 >GILD

7 aug 2025, 20:22 UTC

Winsten

Gilead Sciences 2Q Rev $7.1B >GILD

7 aug 2025, 20:22 UTC

Winsten

Gilead Sciences 2Q Total Liver Disease Sales $211M >GILD

7 aug 2025, 20:22 UTC

Winsten

Gilead Sciences Sees FY Adj EPS $7.95-Adj EPS $8.25 >GILD

7 aug 2025, 20:22 UTC

Winsten

Gilead Sciences 2Q EPS $1.56 >GILD

27 apr 2025, 11:00 UTC

Top Nieuws

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

24 apr 2025, 20:08 UTC

Winsten

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences 1Q Rev $6.67B >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

Peer Vergelijking

Prijswijziging

Gilead Sciences Inc. Prognose

Koersdoel

By TipRanks

11.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 125.52 USD  11.11%

Hoogste 143 USD

Laagste 98 USD

Gebaseerd op 23 Wall Street-analisten die 12-maands prijsdoelen bieden voor Gilead Sciences Inc. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

23 ratings

18

Buy

5

Hold

0

Sell

Technische score

By Trading Central

97.33 / 103.17Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

44 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.